Editas Medicine (EDIT) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free EDIT Stock Alerts $7.72 -0.41 (-5.04%) (As of 03/18/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineShort Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Increases By 7.4%marketbeat.com - March 18 at 7:26 PMEditas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)seekingalpha.com - March 13 at 7:58 PMEditas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)seekingalpha.com - March 12 at 3:56 PM1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.fool.com - March 7 at 3:31 AMEditas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)seekingalpha.com - March 6 at 5:05 PM1 Beaten-Down Stock With 55% Upside, According to Wall Streetfool.com - March 4 at 10:30 AMTrexquant Investment LP Purchases 107,776 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - March 4 at 6:37 AMWhy Editas Medicine Stock Soared as Much as 42% Higher This Weekfool.com - March 2 at 9:49 PMEditas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Analystsmarketbeat.com - March 2 at 2:14 AMStrong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive Optimismmarkets.businessinsider.com - March 1 at 10:17 AMHold Rating on Editas Medicine Pending Clinical Trial Outcomes and Market Differentiation Potentialmarkets.businessinsider.com - February 29 at 1:51 PMEditas Medicine (NASDAQ:EDIT) Price Target Raised to $16.00 at Citigroupmarketbeat.com - February 29 at 12:44 PMQ4 2023 Editas Medicine Inc Earnings Callfinance.yahoo.com - February 29 at 1:24 AMEditas Medicine files for mixed shelf offeringmsn.com - February 28 at 8:23 PMEditas Medicine Shares Rally After Reni-cel Study Upgrademarketwatch.com - February 28 at 3:23 PMEditas Medicine (NASDAQ:EDIT) Shares Gap Up on Analyst Upgrademarketbeat.com - February 28 at 10:25 AMEditas Medicine GAAP EPS of -$0.23 beats by $0.23, revenue of $60.04M beats by $52.32Mmsn.com - February 28 at 10:22 AMHere's what Wall Street expects from Editas Medicine's earnings reportmarkets.businessinsider.com - February 28 at 10:22 AMEditas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing Trialsfinance.yahoo.com - February 28 at 10:22 AMEditas spikes as Vertex Pharma deal boosts Q4 toplinemsn.com - February 28 at 10:22 AMEditas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updatesglobenewswire.com - February 28 at 7:00 AMEarnings Outlook For Editas Medicinebenzinga.com - February 27 at 1:51 PMEditas Medicine Q4 2023 Earnings Previewmsn.com - February 27 at 1:51 PMHealthcare of Ontario Pension Plan Trust Fund Takes $944,000 Position in Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - February 27 at 6:37 AMEDIT Mar 2024 7.000 putfinance.yahoo.com - February 24 at 11:13 AMEDIT Mar 2024 12.000 callca.finance.yahoo.com - February 24 at 6:12 AMQRG Capital Management Inc. Invests $635,000 in Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - February 23 at 6:20 AMEditas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Eventsglobenewswire.com - February 21 at 7:00 AMRafferty Asset Management LLC Sells 80,327 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)marketbeat.com - February 20 at 6:53 AMWall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Tradefinance.yahoo.com - February 19 at 1:14 PMEditas Medicine, Inc. (EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)seekingalpha.com - February 13 at 1:14 PMTwo GV partners on biotech’s reset and building their next drug startupsfinance.yahoo.com - February 13 at 9:35 AMNASDAQ:EDIT (Editas Medicine)fool.ca - February 12 at 8:32 AMEditas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)seekingalpha.com - February 7 at 2:00 PMEditas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analystsmarketbeat.com - February 6 at 2:13 AMEditas Medicine to Participate in Upcoming Investor Conferencesfinance.yahoo.com - January 31 at 1:59 PMEditas Medicine (NASDAQ:EDIT) shareholders have endured a 87% loss from investing in the stock three years agofinance.yahoo.com - January 25 at 10:21 AMLeerink Partnrs Weighs in on Editas Medicine, Inc.'s Q1 2024 Earnings (NASDAQ:EDIT)marketbeat.com - January 19 at 7:47 AMEditas Medicine, Inc. (NASDAQ:EDIT) Sees Significant Decline in Short Interestmarketbeat.com - January 17 at 2:00 PM7 Mighty Healthcare Stocks Changing the Game of Medicinemarkets.businessinsider.com - January 17 at 1:21 PMEditas Medicine (NASDAQ:EDIT) Stock Rating Lowered by StockNews.commarketbeat.com - January 17 at 1:21 AMOptimistic Outlook for Editas Medicine Driven by Therapeutic Development and Regulatory Advancementsmarkets.businessinsider.com - January 12 at 12:48 PMEditas Medicine, Inc. (NASDAQ:EDIT) Expected to Earn FY2024 Earnings of ($3.09) Per Sharemarketbeat.com - January 12 at 7:15 AMEditas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Hold" by Analystsmarketbeat.com - January 12 at 2:53 AMBuy Rating for Editas Medicine Backed by Strong SCD Program and Promising Clinical Developmentsmarkets.businessinsider.com - January 10 at 8:31 AMEditas Medicine, Inc. (EDIT) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)seekingalpha.com - January 10 at 12:43 AMEditas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 8 at 8:47 AMEditas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 10:21 AMShort Interest in Editas Medicine, Inc. (NASDAQ:EDIT) Drops By 5.1%marketbeat.com - January 3 at 7:21 AM2 gene-editing stocks reshaping hereditary disease treatments marketbeat.com - January 2 at 7:15 AM Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address The AI Bottleneck No One is Talking About (Ad)Renewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever. Click here to see who's preparing to meet these needs EDIT Media Mentions By Week EDIT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼0.170.63▲Average Medical News Sentiment EDIT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼43▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Novavax News Today Fusion Pharmaceuticals News Today Cullinan Oncology News Today Exscientia News Today C4 Therapeutics News Today Fate Therapeutics News Today Allogene Therapeutics News Today Alector News Today HilleVax News Today Replimune Group News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.